8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

This study has been completed.
Sponsor:
Information provided by:
Dynogen Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00230581
First received: September 29, 2005
Last updated: October 12, 2007
Last verified: October 2007

September 29, 2005
October 12, 2007
September 2005
Not Provided
GI Transit
Same as current
Complete list of historical versions of study NCT00230581 on ClinicalTrials.gov Archive Site
Patient Reported Outcomes
Same as current
Not Provided
Not Provided
 
8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea

In this study, female patients with IBS-d will be treated for 8 weeks to assess the safety and effectiveness of DDP225 on GI transit and in reducing IBS symptoms.

This is a randomized, double-blind, placebo controlled, multicenter study designed to assess the safety and efficacy of DDP225 in patients with IBS-d. Female patients from 18 to 65 years of age with a history of IBS-d for at least 6 months are potentially eligible for entry into the study. A total of 88 eligible patients with IBS-d will be studied.

The total duration of study participation for an individual patient is approximately 10 weeks (74 days) from the initial screening visit to final study evaluations. The total duration of dosing with study medication (either DDP225 or placebo) is 8 weeks.

Patients who satisfy all of the inclusion criteria and none of the exclusion criteria are eligible to enter the Treatment Period and will be randomly assigned to one of four treatment groups.

After a patient is randomized and enters the Treatment Period, she will take the appropriate study medication once a day for 56 days and return to the clinic at two week intervals for a total of four visits during the Treatment Period. During the Treatment Period, patients will maintain a daily diary and complete questionnaires. One week after completing the 56-day Treatment Period, patients return to the clinic for final safety evaluations which include a physical examination, electrocardiogram, and clinical laboratory testing.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Irritable Bowel Syndrome
Drug: DDP225
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
88
August 2007
Not Provided

Inclusion Criteria:

  1. Female patients from 18 to 65 years of age, inclusive.
  2. History of IBS-d for at least 6 months prior to the initial screening visit.
  3. Endoscopic/radiologic bowel evaluation to rule out cancer, obstruction, or other structural disease.
  4. The patient must have completed at least six days of assessments in the patient diary in the one week period prior to the second screening visit.
  5. Negative serum and urine pregnancy tests and post-partum for at least one year or not breast feeding at the initial screening visit and throughout the study. For patients able to bear children, an acceptable method of birth control must be used throughout the study. Patients unable to bear children must have documentation of such in the case report form (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]).
  6. Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol.

Exclusion Criteria:

  1. Serious underlying diseases, including psychiatric disorders or current history of conditions affecting bowel transit including biochemical or structural abnormalities, or GI surgery
  2. Clinically significant abnormal examination findings or laboratory tests
  3. Inability to stop taking certain medications, or a planned change in medication (including herbal remedies) which could interfere with study assessments
  4. Use of drugs and or ethanol which may interfere with compliance of study procedures or influence study outcome
  5. Presence of a medical condition which could interfere with the interpretation of study data
  6. Significant use of nicotine or caffeine
Female
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00230581
DDP225-04-006
Not Provided
Not Provided
Dynogen Pharmaceuticals
Not Provided
Study Chair: William Patterson, MD Hotel Dieu Hospital
Dynogen Pharmaceuticals
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP